If you or a loved one has taken Reglan and noticed unusual facial or body movements, you may be concerned about tardive dyskinesia. While Reglan has been a mainstay for gastrointestinal disorders, its long-term use carries a known risk of this involuntary movement disorder. This page explains the risk factors and symptoms that warrant closer monitoring.
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. For patients in Georgia who have developed TD after taking Reglan, understanding the medical facts and legal considerations, including the statute of limitations, is critical. Tardive dyskinesia is characterized by involuntary, repetitive movements, often of the face, tongue, or extremities. The condition can be disfiguring and may persist even after the medication is stopped. The FDA-approved labeling for Reglan explicitly warns that metoclopramide can cause TD, and that the risk increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also states that Reglan is contraindicated in patients with a history of TD and that the drug should be used for the shortest possible duration, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For gastroesophageal reflux, the maximum approved treatment duration is 12 weeks, and for diabetic gastroparesis, treatment should not exceed 12 weeks unless longer use is unavoidable, in which case monitoring for TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The mechanistic link between Reglan and TD involves metoclopramide's action as a dopamine receptor antagonist. Chronic blockade of dopamine receptors in the brain's basal ganglia can lead to supersensitivity and abnormal involuntary movements. This pathway is well-documented in the medical literature and is reflected in the drug's labeling, which notes that metoclopramide can cause TD and may also suppress or partially suppress its signs, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also warns against concomitant use with other drugs known to cause TD or extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central issue. The FDA has required a boxed warning on Reglan since 2009, highlighting the risk of TD and the importance of limiting treatment duration. However, many patients were prescribed Reglan for extended periods, sometimes years, before the boxed warning was added or despite it. For affected individuals, the timeline between exposure and documented harm is crucial. TD can develop during treatment, after discontinuation, or even months later. The labeling advises immediate discontinuation of Reglan if signs or symptoms of TD appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
For patients in Georgia considering legal action, the statute of limitations is a key factor. In Georgia, the statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally two years from the date the injury was discovered or reasonably should have been discovered. This means that if a patient developed TD after taking Reglan, they typically have two years from the time they became aware of the condition and its potential link to the medication to file a lawsuit. However, there may be exceptions, such as cases involving fraud or continuous treatment, so consulting with an attorney experienced in pharmaceutical litigation is essential. Attorney-related considerations for affected patients include gathering medical records that document the prescription and use of Reglan, the onset of TD symptoms, and any diagnoses or treatments received. It is also important to preserve the medication packaging and any communications with healthcare providers about the risks. An attorney can help assess whether the warnings provided were adequate and whether the prescribing physician followed recommended guidelines for duration of use. In summary, Reglan use is associated with a serious risk of tardive dyskinesia, and the drug's labeling emphasizes the need for short-term use and monitoring. For Georgia patients who have developed TD, the statute of limitations generally provides two years from discovery of the injury to file a claim. Given the complexity of these cases, legal counsel should be sought promptly to protect rights and explore potential remedies.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Georgia, the statute of limitations for personal injury claims, including those related to prescription drug injuries like tardive dyskinesia from Reglan, is generally two years from the date the injury was discovered or reasonably should have been discovered. It is important to consult with an attorney promptly to ensure your claim is filed within this timeframe.
Key evidence includes medical records documenting the prescription and use of Reglan, the onset of tardive dyskinesia symptoms, and any diagnoses or treatments received. Also preserve medication packaging and communications with healthcare providers about the risks. An attorney can help assess the adequacy of warnings and whether the prescribing physician followed recommended guidelines.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Reglan exposure and a related diagnosis may request an independent, no-cost eligibility review.